Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eagle Swats More Vasopressin Hurdles As Petition And Injunction Are Denied

FDA Intends To Refer Par Citizen Petition To US Federal Trade Commission

Executive Summary

In a clean sweep for Eagle Pharmaceuticals, following its recent approval for the first generic version of Par’s Vasostrict, the ANDA sponsor has seen defeated a Par citizen petition and dodged injunctive action launched by the Endo subsidiary.

You may also be interested in...



Eagle Aims To Meet Extra Vasopressin Demand Caused By Covid

Eagle management provided detailed insight into the existing market for vasopressin, which it entered in January with the first generic version of Endo’s Vasostrict. The US-based player believes operating cash flows for the year, boosted also by its Pemfexy (pemetrexed) launch, could top $170m, paving the way for a major acquisition.

Eagle Victory Clears Way For US Vasopressin Launch

Eagle Pharmaceuticals has celebrated a US court ruling that clears the way for it to launch its generic vasopressin rival to Endo’s Vasostrict. However, the company is still waiting for FDA approval after its application was delayed by a CRL earlier this year, with a new action date provided by the agency.

Eagle Hit With Double Whammy On Vasopressin ANDA Product

Eagle Pharmaceuticals was gearing up for patent-litigation proceedings with Endo over Vasostrict on 1 February but has quickly seen the landscape shift.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB151515

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel